Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:45 a.m. ET. The live webcast ...

WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica” or the "Company”) (Nasdaq: VRCA ...

Esperion (ESPR) announced that following meetings with the U.S. Food and Drug Administration, it has gained alignment on a regulatory path ...

Esperion Therapeutics has a 1 year low of $1.47 and a 1 year high of $3.94. The business’s 50-day moving average is $1.84 and its 200 day moving average is $2.07. Institutional Trading of ...

Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases ...

Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.

ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allurion Technologies (ALUR – Research Report) ...

March 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.